Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

FertirelinvsTriptorelin

A potent GnRH analog designed to support reproductive function in veterinary and research settings

GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones

Hormone SupportHormone Support

At a Glance

Quick
comparison

Dose Range

Fertirelin

25 micrograms–100 micrograms mg

Triptorelin

0.1 mg–22.5 mg mg

Frequency

Fertirelin

Once daily

Triptorelin

Once daily

Administration

Fertirelin

Intramuscular injection

Triptorelin

Intramuscular injection

Cycle Length

Fertirelin

Ongoing/indefinite

Triptorelin

Ongoing/indefinite

Onset Speed

Fertirelin

Moderate (1-2 weeks)

Triptorelin

Moderate (1-2 weeks)

Evidence Level

Fertirelin

Moderate human trials (Phase 1-2)

Triptorelin

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

Fertirelin
Triptorelin

Reproductive Synchronization

Fertirelin82%
Triptorelin0%

Hormone Support

Fertirelin78%
Triptorelin0%

Veterinary Breeding Enhancement

Fertirelin74%
Triptorelin0%

Hormone Regulation

Fertirelin0%
Triptorelin94%

Cancer Management

Fertirelin0%
Triptorelin90%

Endometriosis Relief

Fertirelin0%
Triptorelin87%

Technical Data

Compound
specifications

Fertirelin

Molecular Formula

C55H76N16O12

Molecular Weight

1153.3 g/mol

Half-Life

Variable depending on formulation; sustained-release formulations extend duration

Bioavailability

High when administered via injection

CAS Number

66002-66-2

Triptorelin

Molecular Formula

C64H82N18O13

Molecular Weight

1311.4 g/mol

Half-Life

2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)

Bioavailability

~100% (intramuscular/subcutaneous injection)

CAS Number

57773-63-4

Applications

Best
suited for

Fertirelin

Livestock breeding programs

Fertirelin is particularly well-suited for individuals focused on livestock breeding programs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Reproductive synchronization in cattle

Fertirelin is particularly well-suited for individuals focused on reproductive synchronization in cattle. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Fertility enhancement in veterinary settings

Fertirelin is particularly well-suited for individuals focused on fertility enhancement in veterinary settings. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Research on reproductive hormone mechanisms

Fertirelin is particularly well-suited for individuals focused on research on reproductive hormone mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Triptorelin

Managing advanced prostate cancer when combined with other treatments

Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Relieving severe endometriosis pain and symptoms

Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Delaying puberty development in children with early sexual maturation

Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Side
effects

Fertirelin

Common

  • Mild discomfort at treatment site
  • Transient hormone fluctuations
  • Temporary behavioral changes in animals
  • Mild injection site reactions
  • Short-term changes in appetite
  • Temporary mood variations
  • Minimal systemic effects at therapeutic doses

Uncommon

  • Occasional swelling at injection site

Serious

  • Severe allergic reaction

Triptorelin

Research Status

Safety
& evidence

Fertirelin

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Fertirelin is a GnRH agonist developed specifically for veterinary use in livestock, particularly cattle breeding and fertility management. The peptide has been safely used in veterinary medicine for over 40 years with a well-documented safety profile in animals. Important limitation: Fertirelin is NOT approved for human use. All safety and efficacy data comes from veterinary applications in cattle and limited laboratory research. Human safety data is minimal and extrapolation from veterinary use is problematic. The biphasic response (initial hormone surge followed by suppression) must be carefully managed in any application. Individual responses can vary significantly based on age, hormonal status, and concurrent medications.

Contraindications

  • xPregnancy (may disrupt existing pregnancy)
  • xHypersensitivity to GnRH analogs
  • xActive reproductive infections
  • xConcurrent use with certain medications
  • xUndiagnosed reproductive disorders

Triptorelin

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.

Contraindications

  • xPregnancy (can affect fetal development)
  • xUndiagnosed vaginal bleeding
  • xKnown hypersensitivity to GnRH agonists
  • xSevere untreated depression
  • xActive spinal cord compression in prostate cancer (requires urgent decompression)

Decision Guide

Which is
right for you?

Choose Fertirelin if...

  • Livestock breeding programs
  • Reproductive synchronization in cattle
  • Fertility enhancement in veterinary settings
  • Research on reproductive hormone mechanisms

Choose Triptorelin if...

  • Managing advanced prostate cancer when combined with other treatments
  • Relieving severe endometriosis pain and symptoms
  • Delaying puberty development in children with early sexual maturation